We are live on ! Find out more
EBAC

European Biotech Acquisition Corp. Class A Ordinary Shares
EBAC

Delisted

EBAC was delisted on the 2nd of March, 2023.

Back to rankings

Fund managers haven’t disclosed any holdings of EBAC yet.

EBAC Hedge Fund Activity: Q1 2023 in Review

0 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) for Q1 2023, worth a combined $0 — down 100% from $94M a quarter earlier.

Sellers outnumbered buyers: 50 funds closed out of EBAC and 0 opened new positions — a net loss of 50 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Glazer Capital LLC, exiting entirely with an estimated $12.7M sold.

  • 0 institutional investors held European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) as of Q1 2023, down from 50 in Q4 2022.
  • Funds reported $0 of European Biotech Acquisition Corp. Class A Ordinary Shares stock for Q1 2023, down 100% quarter-over-quarter.
  • 0 funds opened new European Biotech Acquisition Corp. Class A Ordinary Shares positions in Q1 2023 and 50 closed out, a net change of -50 holders.
  • The largest European Biotech Acquisition Corp. Class A Ordinary Shares seller in Q1 2023 was Glazer Capital LLC, an estimated $12.7M sold.

Based on aggregated 13F filings for Q1 2023.